Performance in Delivering - Q2: 2016/2017 (1st October 2015 - 30th September 2016) - non HRA studies

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Target number of patients	Date Agreed to recruit target number of patients	Total number of patients recruited	Date Trial closed to recruitment	Reason for closure
14/SC/0262	151493	CCRN 3322 SAFARI (AMD) A Phase IV, prospective, open-label, uncontrolled, European Study in patients with neovascular Age-related macular degeneration (nAMD), evaluating the efficacy and safety of switching From intravitreal Aflibercept to RanIbizumab 0.5mg.	5	30/10/2016	1	17/11/2015	Withdrawn by Sponsor
14/NW/0130	149373	RESPONSE (NT100) "A randomised, double blind, multi-center, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NT100 in pregnant women with a history of unexplained recurrent pregnancy loss (RPL)."	5	30/06/2015	8	08/12/2015	Recruitment finished
14/EM/0001	144027	TREND (CRFB002A2411) A 12-month, phase IIIb, randomized, visual acuity, assessor-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in treat and extend regimen compared to monthly regimen, in patients with neovascular age-related macular degeneration	6	17/12/2015	3	17/12/2015	Recruitment finished

13/LO/1686	136550	ECLIPSE: Fovista™ and Lucentis® compared to Lucentis® alone in patients with AMD (Ophthotech) A Phase 3 randomised, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (Anti PDGF-B pegylated aptamer) administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal neovascular age-related macular degeneration.	5	30/11/2015	3	30/11/2015	Recruitment finished
14/YH/1090	158372	QUIET-1 - A Balanced Randomised Placebo Controlled Double-blind Phase IIa Study to Investigate the Efficacy and Safety of AUT00063 Versus Placebo in SubjectiveTinnitus	4	31/12/2015	1	08/10/2015	Withdrawn by Sponsor
13/EM/0476	141728	ABSORB: A post-market registry of patients with de novo lesions in previously untreated vessels treated with Absorb BVS	33	17/11/2014	1	06/10/2015	Recruitment finished
13/EE/0276	136890	HCV -Phase 3B study assessing SOF/RBV and SOF/PEG/RBV for Genotype 2 or 3 C	10	09/10/2015	4	09/10/2015	Recruitment finished
15/LO/1166	178877	HARRIER: A Two-Year, Randomized, Double-Masked, Multicenter, Two-Arm Study Comparing the Efficacy and Safety of RTH258 6 mg Versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration	4	25/04/2016	6	25/04/2016	Recruitment finished
14/NW/1068	137300	A Phase 2 randomised, double blind, parallel cohort study of neoadjuvant letrozole + GDC-0032 Versus Letrozole + Placebo in Post Menopausal Women with ER+/HER2 Primary Breast Cancer	6		1	05/08/2016	Recruitment finished

15/LO/0413	171579	BEACON - Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration	5	31/08/2016	8	31/08/2016	Recruitment finished
15/NE/0086	164686	CHROMA: GX29176 Lampalizumab in Geographic Atrophy	2	30/09/2016	0	30/09/2016	Recruitment finished
15/LO/1015	182526	AQUA: Open-label, Phase 4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment	4	31/05/2016	1	31/05/2016	Recruitment finished